MAGELLAN-I: Novel regimen yields strong results in experienced patients with RAVs

BARCELONA —  Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a pangenotypic NS5A inhibitor, produced sustained virologic response rates around 90% in a cohort of treatment-experienced patients, including those with resistance-associated variants, according to findings presented at the International Liver Congress. Fred Poordad, MD, of The...

Read More